Pharmacokinetic variables of moxifloxacin in healthy male camels following intravenous and intramuscular administration

Journal of Veterinary Pharmacology and Therapeutics

Volumn 30, Issue 6, 2007, Pages 586-591

  Abd El Aty, A M ^a,b   Goudah, A ^b   Shah, S S ^c   Shin, H C ^a   Shimoda, M ^c   Shim, J H ^d  

^a Konkuk University   (South Korea)

^b Cairo University   (Egypt)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DANOFLOXACIN; MOXIFLOXACIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CAMEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; CAMELS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE; QUINOLINES;

CAMELIDAE;

EID: 35848944661     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2007.00908.x     Document Type: Article

References (40)

1. Aliabadi, F.S., Ali, B.H., Landoni, M.F. Lees, P. (2003) Pharmacokinetics and PK-PD modeling of danofloxacin in camel serum and tissue cage fluids. Veterinary Journal, 165, 104 118.
2. Bengoumi, M. Faye, B. (2002) Camel diseases and heard management in dry area. 53rd FEZ-F-AAP Annual Meeting, Guide de l'élevage du dromadaire, Sanofi Santè-Nutrition Animale, Libourne, France.
3. Bennett, J.V., Brodie, J.L., Benner, E.J. Kirby, W.M. (1966) Simplified, accurate method for antibiotic assay of clinical specimens. Applied Microbiology, 14, 170 177.
4. Betriu, C., Redondo, M., Palau, M.L., Sanchez, A., Gómez, M., Culebras, E., Boloix, A. Picazo, J.J. (2000) Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrobial Agents and Chemotherapy, 44, 1838 1841.
5. British Society for Antimicrobial Chemotherapy Working Party (1991) A Guide to Sensitivity Testing. British Society for Antimicrobial Chemotherapy, Birmingham, UK.
6. Brown, S.A. (1996) Fluorquinolones in animal health. Journal of Veterinary Pharmacology and Therapeutics, 19, 1 14.
7. Carceles, C.M., Serrano, J.M., Marin, P., Escudero, E. Fernandez-Varon, E. (2006) Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. Journal of Veterinary Medicine Series A, 53, 300 304.
8. Carceles, C.M., Villamayor, L., Escudero, E., Marin, P. Fernandez-Varon, E. (2007) Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. Veterinary Journal, 173, 452 455.
9. Chin, T.F. Lach, J.L. (1975) Drug diffusion and bioavailability: tetracycline metallic chelation. American Journal of Hospital Pharmacy, 32, 625 629.
10. Christensen, J.M., Smith, B.B., Murdane, S.B. Hollingshead, N. (1996) The disposition of five therapeutically important antimicrobial agents in llamas. Journal of Veterinary Pharmacology and Therapeutics, 19, 431 438.
11. Craig, A.W. Suh, B. (1980) Protein binding and the antibacterial effects. Method for determination of protein binding. In Antibiotics in Laboratory Medicine. Ed. Lorian, V., pp. 265 297. Williams and Wilkins, Baltimore, MD.
12. Drlica, K. Zhao, X. (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews, 61, 377 392.
13. Drusano, G.L., Johnson, D.E., Rosen, M. Standiford, H.C. (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agents in a neutropenic rat model of pseudomonas sepsis. Antimicrobial Agents and Chemotherapy, 37, 483 490.
14. Fernandez-Varon, E., Bovaira, M.J., Espuny, A., Escudero, E., Vancraeynest, D. Carceles, C.M. (2005) Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. Journal of Veterinary Pharmacology and Therapeutics, 28, 343 348.
15. Fernandez-Varon, E., Villamayor, L., Escudero, E., Espuny, A. Carceles, C.M. (2006) Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. Veterinary Journal, 172, 302 307.
16. Gabler, W.L. (1991) Fluxes and accumulation of tetracyclines by human blood cells. Research Communications in Chemical Pathology and Pharmacology, 72, 39 51.
17. Gandolf, A.R., Papich, M.G., Bringardner, A.B. Atkinson, M.W. (2005) Pharmacokinetics after intravenous, subcutaneous, and oral administration of enrofloxacin to alpacas. American Journal of Veterinary Research, 66, 767 771.
18. Gardner, S.Y., Davis, J.L., Jones, S.L., Lafevers, D.H., Hoskins, M.S., Mcarver, E.M. Papich, M.G. (2004) Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing. Journal of Veterinary Pharmacology and Therapeutics, 27, 57 60.
19. Gavrielli, R., Yagil, R., Ziv, G., Creveld, C.V. Glickman, A. (1995) Effect of water deprivation on the disposition kinetics of enrofloxacin in camels. Journal of Veterinary Pharmacology and Therapeutics, 18, 333 339.
20. Gibaldi, M. Perrier, P. (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York.
21. Laraje, R., Talmi, A., Bounaga, R., Bengoumi, M., El Hraiki, A. Laurentie, M. (2006) Comparative pharmacokinetics of marbofloxacin after a single intramuscular administration at two dosages to camels (Camelus dromedaries). Journal of Veterinary Pharmacology and Therapeutics, 29, 229 231.
22. Lode, H., Borner, K. Koeppe, P. (1998) Pharmacodynamics of fluoroquinolones. Clinical Infectious Diseases, 27, 33 39.
23. Odenholt, I. Bengtsson, S. (1994) Postantibiotic-effect and postantibiotic effect of subinhibitory concentrations of sparfloxacin on gram-negative bacteria. Chemotherapy, 40, 30 36.
24. Odenholt, I., Löwdin, E., Gustafsson, I. Cars, O. (2002) Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model. Antimicrobial Agents and Chemotherapy, 46, 2046 2048.
25. Oukessou, M., Berrag, B. Alvinerie, M. (1999) A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). Veterinary Parasitology, 83, 151 159.
26. Pea, F., Pavan, F., Lugatti, E., Dolcet, F., Talmassons, G., Screm, M.C. Furlanut, M. (2006) Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Clinical Pharmacokinetics, 45, 287 295.
27. Powers, J. (1990) Statistical analysis of pharmacokinetic data. Journal of Veterinary Pharmacology and Therapeutics, 13, 113 120.
28. Schmidt-Nielsen, K., Schmidt-Nielsen, B., Houpt, T.R. Jarnum, S.A. (1956) Water balance of the camel. American Journal of Physiology, 185, 185 194.
29. Siefert, H.M., Domdey-Bette, A., Henninger, K., Hucke, F., Kohlsdorfer, C. Stass, H.H. (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. The Journal of Antimicrobial Chemotherapy, 43 (Suppl. B 69 76.
30. Spreng, M., Deleforge, J., Thomas, E., Boisrame, B. Drugeon, H. (1995) Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. Journal of Veterinary Pharmacology and Therapeutics, 18, 284 289.
31. Stass, H. Kubitza, D. (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. The Journal of Antimicrobial Chemotherapy, 43, 83 90.
32. Stass, H., Kubitza, D., Moller, J.G. Delesen, H. (2005) Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. British Journal of Clinical Pharmacology, 59, 536 541.
33. Toutain, P.L. Lees, P. (2004) Integration and modeling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics, 27, 467 477.
34. Turnidge, J. (1999) Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs, 58, 29 36.
35. Wilson, R.T. (1984) The Camel, pp. 69 77. Longman Group Limited, Longman House, Essex, UK.
36. Wolfson, J.S. Hooper, D.C. (1989) Fluoroquinolone antimicrobial agents. Clinical Microbiology Reviews, 2, 378 424.
37. Woodcock, J.M., Andrews, J.M. Boswell, F.J. (1997) In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy, 41, 101 106.
38. Yamaoka, K., Nakagawa, T. Uno, T. (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmaceutics, 6, 165 175.
39. Yamaoka, K., Tanigawara, Y., Nakagawa, T. Uno, T. (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobiological Dynamics, 4, 879 885.
40. Zlotos, G., Bucker, A., Kinzig-Schippers, M., Sorgel, F. Holzgrabe, U. (1998) Plasma protein binding of gyrase inhibitors. Journal of Pharmaceutical Science, 87, 215 220.